CT Myocardial Perfusion to Guide the Diagnosis and Treatment of Patients With Stable Coronary Artery Disease (POTENTIAL)

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Oct 31, 2023

Keywords

ClinConnect Summary

The POTENTIAL trial is studying how effective a specific type of imaging test, called CT myocardial perfusion imaging (CT-MPI), is for helping doctors make treatment decisions for patients with stable coronary artery disease (CAD). The trial aims to see if using this imaging test can reduce the need for invasive procedures like coronary angiography (a test to look at the heart's blood vessels) within 90 days and to check for any serious heart problems over the next year.

To participate in this trial, you need to be at least 18 years old and have stable chest pain, along with a specific level of narrowing in your heart's blood vessels. However, if you have certain conditions like a recent heart attack, severe heart failure, or if you are pregnant or trying to become pregnant, you won't be eligible. If you join the trial, you will undergo the CT-MPI test and then be followed up to see how it impacts your care and any health issues that may arise. This trial is currently recruiting participants and is open to individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Patients with stable chest pain who have undergone coronary CT angiography and have 50-90% stenosis in at least one vessel \> 2mm in diameter
• • Able to provide signed informed consent
• Exclusion Criteria:
• • Suspected or confirmed acute coronary syndrome
• • Evidence of clinical instability or need for an emergent procedure
• • History of percutaneous coronary stent implantation, history of coronary artery bypass grafting, or history of myocardial infarction
• • Left main artery stenosis ≥ 50%
• • Severe heart failure (New York Heart Association (NYHA) ≥III)
• • Estimated glomerular filtration rate \< 60 mL/min/1.73 m2
• • Contraindicated to use contrast agents, beta-blockers, nitrates or adenosine drugs
• • Acute episodes of bronchial asthma or chronic obstructive pulmonary disease
• • II or III degree atrioventricular block
• • History of pacemaker or implantable cardioverter defibrillator implantation
• • Combined with other cardiovascular diseases including cardiomyopathy, congenital heart disease, valvular heart disease, pulmonary vascular disease, pericardial disease, etc
• • Pregnant or trying to be pregnant
• • Combined with any other serious disease, life expectancy \<1 year
• • Any condition leading to possible inability to comply with the protocol procedures and follow-up
• • Currently participating in any other clinical trials